Published in Gene Therapy Weekly, December 22nd, 2005
"Improving cellular uptake and biodistribution remains one of the major obstacles for a successful and broad application of PNAs as antisense therapeutics. Recently, we reported the identification and functional characterization of an antisense PNA, which redirects splicing of murine CD40 pre-mRNA."
"In this context," wrote K. Albert-Shofer and colleagues, ISIS Pharmaceutical, "it was discovered that a simple octa(L-Lys) peptide covalently linked to the PNA is...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.